Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

FDA releases guidance to speed personalized drug development

By Nancy Crotti | January 4, 2021

The FDA today released draft guidance designed to make it easier for researchers to seek approvals for drugs designed for individuals with severe genetic diseases.

The draft guidance focuses on investigational new drug submissions for antisense oligonucleotide (ASO) products because these are the most common drugs being developed for severely debilitating or life-threatening genetic diseases. ASOs target messenger RNA and may help people for whom there is no adequate available therapy and who need prompt medical intervention because of rapid disease progression.

The draft guidance also targets academic investigators who may be less familiar with FDA regulations, policies and practices, and less experienced than biopharmaceutical or pharmaceutical companies in working with the agency. It includes information on:

  • The approach to obtaining feedback from the FDA.
  • The expectations and process for making regulatory submissions to the agency.
  • Recommendations about the requirement for Institutional Review Board (IRB) review of the protocols within the guidance.
  • Information on how to obtain informed consent.

“We also are optimistic that development of these individualized drug products may spur gene sequencing that leads to the development of additional individualized drug products for the same disease (though perhaps caused by a different mutation),” said Dr. Patrizia Cavazzoni, acting director of the FDA’s Center for Drug Evaluation and Research, in a news release. “For this approach to drug development, we need to determine — collectively — how to effectively bring these drug products to all who need them. If we have the scientific ability to develop drug products for these rare diseases, we need to find a way to bring them to patients while ensuring there is the right balance of risk to benefit. This guidance, which provides clarity on the early development and IND submission process, is the FDA’s first step in working with those who are developing these individualized drug products.”

You can read the draft guidance here.

 

 

Tell Us What You Think! Cancel reply

Related Articles Read More >

Johnson & Johnson
8 things to keep in mind related to the FDA advisory meeting on J&J vaccine
master mixes
Air-dryable master mixes replace lyophilization in the manufacturing of molecular assays
COVID-19 therapies vaccines coronavirus
Could a third vaccine shot better protect against COVID-19 variants?
Kala Pharmaceuticals slides on missed Q4 projections

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards